Melanotan II: Evidence, Mechanism, Risks & Legal Status

Melanotan II is a synthetic, cyclic alpha-melanocyte-stimulating-hormone (alpha-MSH) analog originally engineered at the University of Arizona as a pharmacologic tool and skin-cancer-prevention concept — to induce protective pigmentation without UV exposure.1 Its popularity for sunless tanning and as a so-called "Barbie drug" is large; its proof in humans is tiny and dated. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Melanotan II is not an FDA-approved drug; it is sold illegally as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision; the safest path for cosmetic tanning is a topical DHA product, not an injectable melanocortin.

What is Melanotan II and how does it work?

MT-II is a synthetic cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, molecular formula C50H69N15O9, molar mass approximately 1024 — a lactam-bridged, conformationally constrained analog of native alpha-MSH.4 The cyclization and the D-Phe substitution dramatically increase potency and metabolic stability versus the native linear hormone, the design rationale of Hruby and Hadley's University of Arizona program.1

The core mechanism is polypharmacology: MT-II is a non-selective agonist across the melanocortin GPCR family — MC1R, MC3R, MC4R and MC5R.4 Activation of MC1R on melanocytes raises intracellular cAMP via adenylyl cyclase, drives PKA signaling, upregulates tyrosinase, and increases eumelanin synthesis — producing tanning independent of UV light.5 Central MC4R in the hypothalamus is the principal mediator of MT-II's sexual-arousal and appetite-suppression effects, a centrally driven mechanism distinct from the vascular action of PDE5 inhibitors; MC3R and MC5R contribute to energy balance, inflammation and sebaceous/immune effects.1 Critically, MT-II crosses the blood-brain barrier and engages central MC4R, which is why nausea and erections appear at tanning doses — the central effects cannot be dialed out, the key liability that halted its development.1 Robust human pharmacokinetics for MT-II are not published; the foundational review reports no half-life data for the parent peptide, and the best proxy is its de-aminated metabolite bremelanotide (PT-141), which showed a peak serum concentration near 30 minutes and a serum half-life of roughly 120 minutes in Phase I.1

What is the evidence by indication?

The human evidence base is thin, dated, and limited to a handful of subjects. Every indication below should be read in that light.

The pivotal tanning evidence is the pilot Phase I trial (Dorr et al., Life Sciences 1996), a single-blind, alternating-day, placebo-controlled study in just three healthy men using subcutaneous dosing from 0.01 to 0.025-0.03 mg/kg/day; two of three subjects showed increased facial, upper-body and buttock pigmentation one week after dosing ended, without UV exposure.2 The MC1R-to-cAMP/PKA-to-tyrosinase-to-eumelanin pathway is mechanistically well understood, but no human RCT has confirmed efficacy or safety.5 For contrast, the MC1R-selective sibling afamelanotide (Scenesse, Melanotan I) is FDA-approved (2019) — but for erythropoietic protoporphyria, not cosmetic tanning.4

The erectile effect first emerged as an adverse finding in the 1996 tanning trial, then was formalized in two double-blind crossovers by Wessells and colleagues: in psychogenic ED, eight of ten men achieved erections with greater than 80 percent rigidity lasting a mean 38 minutes versus 3 minutes for placebo; in organic ED, subjective erections followed 63 percent of MT-II injections versus 5 percent of placebo, with increased subjective desire.3 These are genuine controlled human data but tiny and short-duration, and the program pivoted to the cleaner metabolite bremelanotide, which reached FDA approval for female hypoactive sexual desire disorder (Vyleesi, 2019).1 The widely marketed appetite and weight-loss claim, by contrast, rests on rat studies using direct brain infusion — which suppressed food intake by about 30 percent — not the subcutaneous route humans use, so it is preclinical-only.1415 No adequately powered modern RCT exists for any indication; the WADA Prohibited List status can be confirmed at the USADA Prohibited List.19

What doses appear in the literature?

Reported strictly as information, not a protocol — MT-II is unapproved and illegal for human use. All human and gray-market use is subcutaneous injection of reconstituted lyophilized peptide; it is not orally bioavailable.2 The Phase I tanning trial started at 0.01 mg/kg/day SC and escalated by 0.005 mg/kg increments to 0.025-0.03 mg/kg/day, with 0.025 mg/kg/day recommended for future work; the 0.03 mg/kg dose produced Grade II somnolence and fatigue.2 The erectile-function trials used single subcutaneous doses around 0.025 mg/kg (up to 0.157 mg/kg in dose-finding).3 Gray-market users typically self-inject fixed milligram amounts — commonly a roughly 0.25-1 mg loading phase then intermittent maintenance — rather than weight-based dosing, a practice with no safety validation that is directly implicated in the toxicity case reports below.1112 Because the powder is reconstituted at home with no purity, sterility, or content guarantees, the formulation itself adds risk.16

How safe is Melanotan II?

This compound has a high-risk safety profile, with reported adverse events spanning trivial to organ-threatening. Common dose-related effects from the controlled studies include nausea at essentially every dose level, vomiting, facial flushing, spontaneous erections, a characteristic yawning-stretching complex, and somnolence at higher doses.2 The signature dermatologic concern is melanoma-spectrum: a 25-year-old developed sudden multiple new nevi and rapid change in existing ones weeks after a four-week course, with histopathology showing severe dysplasia, and melanoma case reports have been temporally associated with use — often confounded by concurrent sunbed exposure, including a teenage FAMMM-syndrome patient with an enlarging nevus after self-injection plus UV.689 Causation is not proven and the data are case-report level, but the signal is biologically plausible because MT-II activates melanocytes regardless of whether a cell is normal or pre-malignant.7 Melanonychia and oral mucosal pigmentation are also reported.10

Serious systemic events appear in the toxicology literature. Ischemic low-flow priapism has required cavernosal aspiration and intracavernosal phenylephrine, with some cases needing a surgical Winter's shunt and erectile function not recovered at follow-up.13 A 39-year-old man who injected 6 mg subcutaneously developed tachycardia, hypertension, mydriasis, tremor, rhabdomyolysis and renal dysfunction requiring ICU care.12 A previously normotensive man developed hypertension and a right-sided renal infarction affecting roughly half the kidney after 27 mg over six months, attributed to sympathetically driven vasoconstriction; posterior reversible encephalopathy syndrome and hypertensive crises are also reported.11 The FDA has additionally flagged immunogenicity and impurity risks inherent to unregulated peptide products.16 High-caution populations include those with personal or family history of melanoma or FAMMM, uncontrolled hypertension or cardiovascular disease, prior priapism or sickle-cell disease, and pregnancy or lactation where no data exist.11

What is the FDA and WADA status in 2026?

Melanotan II has never been approved by the FDA for any medical, cosmetic, or therapeutic indication; it is treated as an unapproved new drug when sold or marketed for human use, and the FDA has issued warning letters and enforcement actions to distributors.18 In September 2023 the FDA placed MT-II into 503A Category 2 — "significant safety risk" — effectively prohibiting its compounding.16 On April 15, 2026 the FDA removed MT-II (with eleven other peptides including BPC-157 and TB-500) from Category 2, but removal from Category 2 is not authorization to compound; it merely lifts the explicit prohibition label.17 To become compoundable, MT-II must clear a Pharmacy Compounding Advisory Committee review scheduled to convene before February 2027 and then notice-and-comment rulemaking, so it remains FDA-restricted and non-compoundable throughout 2026, with no legal human-use pathway.17

For athletes the picture is unambiguous: MT-II is captured as a peptide hormone under Section S2 of the WADA Prohibited List and should be treated as banned in and out of competition.19 Do not conflate MT-II with its approved relatives — afamelanotide (Scenesse/Melanotan I), an MC1R-selective analog approved for EPP, or bremelanotide (Vyleesi/PT-141), MT-II's metabolite approved for female HSDD.4

Bottom line. MT-II's non-selectivity is an un-fixable design flaw for human use — the very reason industry shelved it and advanced the cleaner metabolite bremelanotide. What is genuinely studied is minimal (Grade B tanning and erection), the popular appetite claim is animal-only (C), and what is hyped is contradicted by a real if confounded dermatologic safety signal plus organ-level toxicity. It remains unapproved, WADA-prohibited, and FDA-restricted in 2026, with key uncertainties — absolute melanoma risk, long-term cardiovascular consequences, and product purity — all unknown precisely because no regulated trial program exists. Regulatory facts here are current as of June 2026 and should be re-verified after the PCAC review.